3 Results for "

miransertib

" in MedChemExpress (MCE) Product Catalog:
Products (3)

3 Results for "miransertib" in MCE Product Catalog:

18
18 Cited Publications
Cat. No.: HY-19719
CAS No.: 1313881-70-7
Synonyms: ARQ-092
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib is effective against Leishmania .
18
18 Cited Publications
Cat. No.: HY-19719A
CAS No.: 1313883-00-9
Synonyms: ARQ-092 hydrochloride
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib hydrochloride (ARQ-092 hydrochloride) is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib hydrochloride is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib hydrochloride is effective against Leishmania .
Cat. No.: HY-19719B
CAS No.: 1817727-88-0
Synonyms: ARQ-092 mesylate
Target:  

Akt Parasite

Research Areas:  

Infection Cancer

Miransertib (ARQ-092) mesylate is a potent, orally active, selective and allosteric Akt inhibitor with IC50s of 2.7 nM, 14 nM and 8.1 nM for Akt1, Akt2, Akt3, respectively. Miransertib mesylate is also a potent the AKT1-E17K mutant protein inhibitor and has the potential for PI3K/AKT-driven tumors and Proteus syndrome research . Miransertib mesylate is effective against Leishmania .